Catalyst Wire Dossier Catalyst Wire Dossier

onCARlytics CF33-CD19

CF33-CD19 CAR-T · Imugene Limited
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for onCARlytics CF33-CD19, covering 2026-03-06 to 2026-03-06. Get the full timeline:

Most recent: Clinical Trial Update: A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS) [Phase 1]

See pricing